Business Context and Reporting Period
Company: Altimmune, Inc. (ALT)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Altimmune is a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases. Its lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for MASH, obesity, Alcohol Use Disorder (AUD), and Alcohol Liver Disease (ALD). The company has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenues | $5 | $5 |
| Net Loss | $(19,575) | $(24,394) |
| Diluted Net Loss Per Share | $(0.26) | $(0.34) |
| Operating Expenses | $21,820 | $26,799 |
| Cash, Cash Equivalents & Restricted Cash | $49,146 | $79,019 |
| Short-term Investments | $100,722 | $94,965 |
| Total Liquidity (Cash + Investments) | $149,868 | $173,984 |
| Accumulated Deficit | $(580,965) | $(490,725) |
| Net Cash Used in Operating Activities | $(16,840) | $(16,357) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $4.8 million (20%) to $19.6 million, driven primarily by a $5.7 million (26%) reduction in Research and Development (R&D) expenses.
- R&D Expense Drivers: The decrease in R&D was due to the winddown of the MOMENTUM Phase 2 obesity trial, reduced manufacturing costs, and lower clinical activity for the IMPACT Phase 2b MASH trial. These were partially offset by the initiation of new AUD and ALD trials.
- Interest Income Decline: Total other income decreased by $0.8 million (35%), primarily due to a $0.9 million drop in interest income earned on cash equivalents and short-term investments.
- Financing Activity: Net cash provided by financing activities turned positive at $34.1 million, compared to a $0.3 million use in the prior year. This was driven by $34.6 million in net proceeds from at-the-market (ATM) equity offerings.
- Tax Benefit: The company recorded a discrete tax benefit of approximately $0.7 million related to carryback claims with the State of Maryland.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Pipeline: Management announced the pursuit of two new indications for pemvidutide: AUD and ALD. A Phase 2 AUD trial is expected to begin in Q2 2025, and a Phase 2 ALD trial in Q3 2025.
- Liquidity Position: Management believes current cash, cash equivalents, and short-term investments ($149.9 million) are sufficient to fund operations for at least 12 months from the filing date.
- Capital Strategy: The company continues to pursue additional equity or debt financing and potential partnerships to fund long-term clinical trials.
Recent Financing and Subsequent Events
- ATM Offerings: During Q1 2025, the company sold approximately 5.3 million shares under its 2023 and 2025 ATM agreements, raising approximately $34.8 million in net proceeds. As of March 31, 2025, $145.3 million remained available under the 2025 Agreement.
- Subsequent Equity Raise: In April 2025, the company raised an additional $16.3 million in net proceeds via the 2025 Offering.
- Debt Facility: On May 13, 2025, the company entered into a Loan and Security Agreement with Hercules Capital, Inc., providing up to $100.0 million in term loans. The first tranche of $15.0 million was funded on the closing date. The loan bears interest at the greater of Prime + 2.45% or 9.95% (until Dec 31, 2025), with an interest-only period of up to 24 months.
Risks and Contingencies
- Legal Proceedings: A shareholder derivative action filed in June 2024 was dismissed without prejudice on February 3, 2025. The company faces no other material pending litigation.
- Regulatory and Political Risk: Risks include potential disruptions at the FDA due to government funding shortages, staffing cuts, or policy changes under the new U.S. presidential administration, which could delay regulatory reviews.
- Debt Covenants: The new term loan includes restrictive covenants regarding liquidity, indebtedness, and asset dispositions. Failure to comply could result in an event of default and acceleration of debt repayment.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $149.9 million liquidity position against the projected burn rate for the new AUD and ALD Phase 2 trials.
- Debt Terms: Review the specific milestones required to unlock the remaining $85 million of the Hercules Capital term loan and the impact of the 9.95% interest rate on future cash flows.
- ATM Capacity: Confirm the remaining capacity under the 2025 ATM agreement ($145.3 million) and the potential for further dilution.
- Clinical Timelines: Monitor the initiation dates for the Phase 2 AUD (Q2 2025) and ALD (Q3 2025) trials and their impact on R&D expense guidance.
- Regulatory Environment: Assess the potential impact of FDA staffing changes or policy shifts under the new administration on the approval timeline for pemvidutide.